标题
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
作者
关键词
-
出版物
NATURE
Volume 586, Issue 7830, Pages 594-599
出版商
Springer Science and Business Media LLC
发表日期
2020-09-30
DOI
10.1038/s41586-020-2814-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- An Infectious cDNA Clone of SARS-CoV-2
- (2020) Xuping Xie et al. Cell Host & Microbe
- Immunology of COVID-19: current state of the science
- (2020) Nicolas Vabret et al. IMMUNITY
- Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults
- (2020) Mark J. Mulligan et al. NATURE
- An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
- (2020) Ugur Sahin et al. NATURE
- A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
- (2020) Xiangyang Chi et al. SCIENCE
- Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
- (2020) Philip J. M. Brouwer et al. SCIENCE
- A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
- (2020) Antonio E. Muruato et al. Nature Communications
- Characterization of HIV-1 nucleoside-modified mRNA vaccines in rabbits and rhesus macaques
- (2019) Norbert Pardi et al. Molecular Therapy-Nucleic Acids
- RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial
- (2019) Fatma Doener et al. VACCINE
- mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials
- (2019) Robert A. Feldman et al. VACCINE
- Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses
- (2018) Norbert Pardi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies
- (2018) Norbert Pardi et al. Nature Communications
- New Vaccine Technologies to Combat Outbreak Situations
- (2018) Susanne Rauch et al. Frontiers in Immunology
- Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening
- (2018) Alexandra G. Orlandini von Niessen et al. MOLECULAR THERAPY
- Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
- (2017) Norbert Pardi et al. NATURE
- Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection
- (2016) Oi-Wing Ng et al. VACCINE
- A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection
- (2016) Wanbo Tai et al. VIROLOGY
- Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes
- (2015) Norbert Pardi et al. JOURNAL OF CONTROLLED RELEASE
- mRNA-based therapeutics — developing a new class of drugs
- (2014) Ugur Sahin et al. NATURE REVIEWS DRUG DISCOVERY
- Evaluation of C-reactive protein as an inflammatory biomarker in rabbits for vaccine nonclinical safety studies
- (2013) Eric Destexhe et al. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
- Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response
- (2012) David N. Taylor et al. VACCINE
- Response definition criteria for ELISPOT assays revisited
- (2010) Z. Moodie et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Selective CD4+ T Cell Help for Antibody Responses to a Large Viral Pathogen: Deterministic Linkage of Specificities
- (2008) Alessandro Sette et al. IMMUNITY
- Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability
- (2008) Katalin Karikó et al. MOLECULAR THERAPY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started